{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-055819","form_type":"8-K","ticker":null,"cik":"0000861838","company_name":"Aceragen, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.461377+00:00","generated_at":"2026-06-15T23:47:09.549052+00:00","sec_items":["2.05","5.02","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Aceragen lays off ~80% of staff, CFO departs; cash runway only into May 2023; FDA lifts clinical hold on ACG-801","bullets":["Approximately 80% of employees terminated effective April 28, 2023; expects ~$4.5M restructuring charges in Q2 2023.","CFO John Kirby departs; CEO John Taylor assumes CFO duties effective immediately.","Existing cash and equivalents fund operations only into May 2023; needs to raise additional capital.","FDA lifts clinical hold on ACG-801 for Farber disease, enabling ADVANCE study subject to financing availability.","Company warns it may need to scale back development, seek a sale, or cease operations if unable to raise capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-055819","json":"https://secwatch.observer/filing/0001104659-23-055819.json","markdown":"https://secwatch.observer/filing/0001104659-23-055819.md","text":"https://secwatch.observer/filing/0001104659-23-055819.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/861838/000110465923055819/0001104659-23-055819-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/861838/000110465923055819/tm2314659d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T23:47:09.549052+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"05a92ca2d7","claim":"John Taylor changed role as Chief Financial Officer at Aceragen, Inc..","evidence_excerpt":"John Taylor, the Company's Chief Executive Officer, has assumed the duties of Chief Financial Officer of the Company as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/861838/000110465923055819/0001104659-23-055819-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"assumed duties of Chief Financial Officer"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"ec9d186c8e","claim":"John Kirby departed as Chief Financial Officer at Aceragen, Inc..","evidence_excerpt":"John Kirby no longer serves as the Company's Chief Financial Officer or is employed by the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/861838/000110465923055819/0001104659-23-055819-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"no longer serves"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"29315b8501dd28a8d6f9c5d52f96807d4e920080","claim":"Aceragen, Inc. announced a restructuring with charges of approximately $4.5 million (approximately 80% of the Company’s employees).","evidence_excerpt":"(the “2022 Form 10-K”). In connection with the Reduction, the Company estimates that it will incur aggregate restructuring charges in the second quarter of 2023 of approximately $4.5 million related to severance payments and other employee-related costs. The Company’s estimates are subject to a number of assumptions, and actual results may differ. The Company may","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/861838/000110465923055819/0001104659-23-055819-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $4.5 million"},{"label":"Headcount","value":"approximately 80% of the Company’s employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}